Unless matched to oncogenic driver mutations through companion diagnostics, clinical trials with targeted drugs are mostly unsuccessful. There is a fundamental gap between the discovery of active targeted drugs and the identification of mechanistic biomarkers needed to utilize their full clinical potential. Filling tis gap is imperative, because it will produce new personalized medicine opportunities for patients who currently have limited therapeutic options. Our long-term goal is to contribute to the improvement of personalized medicine by elucidation of the complex mechanisms of action (MoAs) of targeted drugs in lung cancer thereby revealing targets and pathways with clinical significance. Many targeted drugs, particularly kinase inhibitors, are pleiotropic and their anticancer activity can result from non-obvious, off-target effects. Importantly, our preliminary data strongly indicate beneficial off-target activity of several clinically relevant kinase inhibitrs, namely tivantinib, midostaurin and crizotinib, in non-small cell lung cancer (NSCLC) cells. The objective of this project is to identify the molecular MoAs that underlie these off-target effects n NSCLC. The central hypothesis is that identification of off-target-based anticancer mechanisms will reveal cancer-relevant targets and pathways providing novel personalized oncology opportunities with single drugs and drug combinations. The rationale for the proposed study is that novel targeted therapeutic options in NSCLC critically require predictive biomarkers and that mechanism-based biomarkers provide the greatest clinical value. To test this hypothesis, we will pursue the following specific aims: 1) Identify off-targets and -pathways that are modulated by kinase inhibitors; 2) Characterize the functional relevance of kinase inhibitor off-targets; and 3) Determine the potential for rational drug combinations based on identified off-targets.
In Aim 1, our expertise in combining chemical and phosphoproteomics will be applied to provide a proteome-wide view of each kinase inhibitor's targets and signaling effects.
In Aim 2, the functional relevance of inhibited targets and pathways will be determined by loss-of- function (RNAi, pharmacological inhibition) and rescue experiments (target overexpression, expression of drug- insensitive mutants). The translational potential will be investigated using primary tumor-derived cell lines and tissue samples to propose candidate biomarkers for future patient selection.
Under Aim 3, compounds, which also target those off-target-relevant signaling pathways or which engage parallel pathways that, as evidenced by known driver mutations, are aberrantly activated in these cells, will be selected to examine potential synergistic interactions in vitro and ex vivo. The approach is innovative, because it represents a novel way of evaluating drug-induced phenotypic changes on the cellular level by specifically mining for and molecularly characterizing off-target effects that can be utilized for personalized oncology. The proposed research is significant as it will form the foundation for the discovery of mechanism-based biomarkers that enable successful clinical implementation of these novel therapeutic opportunities.

Public Health Relevance

The proposed research is relevant to public health and supports the NIH's mission because the results will make a major contribution to our understanding of individual oncogenic signaling networks in NSCLC. It will also reveal previously unrecognized opportunities for the clinical development of advanced drug candidates. Matching of these novel therapeutic approaches to mechanistic biomarkers is likely to produce significant survival benefits by providing personalized targeted therapies for a greatly underserved patient population.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83
Mishall, Katie M; Beadnell, Thomas C; Kuenzi, Brent M et al. (2017) Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget 8:103014-103031
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Kuenzi, Brent M; Remsing Rix, Lily L; Stewart, Paul A et al. (2017) Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol 13:1222-1231
Wright, Gabriela; Golubeva, Volha; Remsing Rix, Lily L et al. (2017) Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. ACS Chem Biol 12:1883-1892
Vaishnavi, Aria; Schubert, Laura; Rix, Uwe et al. (2017) EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77:3551-3563
Jhuraney, Ankita; Woods, Nicholas T; Wright, Gabriela et al. (2016) PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Mol Cancer Ther 15:1669-81

Showing the most recent 10 out of 11 publications